Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan Expects Phase I Results Soon From Nation's Only H1N1 Vaccine

This article was originally published in PharmAsia News

Executive Summary

Taiwan trials for the nation's only H1N1 influenza vaccine are expected to be revealed during the next week, according to groups conducting the tests Adimmune's drug

You may also be interested in...



PIC/S Supplements GMP Guidance On Cross Contamination In Shared Facilities

The international group of pharmaceutical inspectorates, PIC/S, has issued an aide-memoire and a Q&A document to support its 2018 guideline on using health-based exposure limits to assess the risk of cross contamination in shared manufacturing facilities.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Sanofi's Sarclisa for treating adults with relapsed and refractory multiple myeloma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal

Progress for two US-based companies in the race to develop a COVID-19 vaccine.

UsernamePublicRestriction

Register

LL1132569

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel